Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.37 |
| ▸ | DPP4 | P27487 | 4/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25246911 | 1.00 | MMP2 (0.44) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL22580860 | 0.84 | MMP2 (0.40) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL29269013 | 0.84 | MMP2 (0.40) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL25837797 | 0.84 | MMP2 (0.40) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL29269009 | 0.84 | MMP2 (0.40) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL25303938 | 0.84 | MMP2 (0.43) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL22557702 | 0.79 | MMP2 (0.44) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL21682405 | 0.79 | MMP2 (0.44) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL19898081 | 0.79 | MMP2 (0.44) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL18340082 | 0.79 | MMP2 (0.44) | MMP2ANPEPDPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262433-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4157834-B1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LTD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| WO-2023099561-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
| WO-2020212350-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020212351-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | USP30, UQCRC1, NDUFAF1 | MMP2 2616/4885ANPEP 2234/4885DPP7 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.